Answers are grounded in this paper and cite their sources.
Systematic review evaluates antimicrobial peptides against Mycobacterium tuberculosis, highlighting rational design and machine learning to overcome translational barriers.
Tuberculosis remains the leading cause of death from a single infectious pathogen, driven by prolonged treatment regimens and escalating drug resistance. Antimicrobial peptides represent a promising alternative therapeutic class with diverse mechanisms and limited resistance emergence. This review distinguishes anti-mycobacterial from anti- Mycobacterium tuberculosis peptides and systematically analyses 22 candidates curated in the APD6 alongside additional literature reports. We evaluate their structural and physicochemical determinants of activity, mechanistic evidence in vitro and in vivo, and synergy with conventional agents. Finally, we discuss rational design strategies, machine learning-guided optimisation, and translational barriers that must be overcome to realise peptide-based tuberculosis therapeutics.
No takes yet. Share an insight, caveat, or question.
Dominic et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: